Sponsored by Genelux Corporation

Late-stage ovarian cancer presents one of the most daunting challenges within oncology. Given the limited treatment options, patients and healthcare providers often find themselves navigating a complex and uncertain journey. The situation highlights a pressing need for expanded treatment avenues, increased research funding, and greater awareness to improve outcomes for those battling this aggressive disease.

Ovarian cancer is well known for its late-stage diagnosis. By the time symptoms manifest, the disease is often advanced, with most of the patients presenting with stage III or IV ovarian cancer. These stages are marked by widespread disease, making treatment more challenging and limiting the effectiveness of current therapies.

Current Treatment Options and Their Limitations

The current standard of care typically includes a combination of surgery and chemotherapy, but in the majority of cases, is not sufficient to eradicate the cancer entirely and the disease has a high propensity for recurrence.

Surgical intervention aims to remove as much of the tumor as possible. However, in late-stage ovarian cancer, surgery may not be feasible or may only offer temporary relief. The decision to proceed with surgery is often complex and depends on the patient's overall health and the extent of the disease.

Chemotherapy remains a cornerstone of treatment for late-stage ovarian cancer. While it can be effective in shrinking tumors and managing symptoms, in many cases it does not guarantee long-term remission. The majority of tumors become resistant or refractory, and the risk of relapse contributes to the ongoing challenge of managing the disease.

Targeted therapies, such as PARP inhibitors, recently approved antibody-drug conjugate, and others have shown potential in earlier lines of treatment of certain subsets of ovarian cancer patients. This is particularly seen in those with specific genetic mutations like BRCA1 or BRCA2 or those whose tumors highly express folate receptor, a specific biomarker. However, these therapies often require a biomarker and hence are not universally applicable and may not be effective for all patients.

Immunotherapy is an emerging area of treatment that harnesses the body's immune system to fight cancer. While still under investigation for ovarian cancer, its potential is being explored in clinical trials.

The limitations of current treatment options underscore the need for new and innovative approaches in managing late-stage ovarian cancer. Ongoing research is crucial in developing new therapies and improving existing ones, with clinical trial participation vital for the advancement of treatment options. Clinical trials offer patients access to cutting-edge therapies and contribute to the development of new treatments. Promoting awareness and access to clinical trials can help ensure that more patients benefit from emerging therapies.

Genelux’s Innovative Approach: Oncolytic Immunotherapy

Genelux Corporation is at the forefront of developing oncolytic immunotherapies. Their lead candidate, 

 (Olvi-Vec), is a proprietary, modified strain of the vaccinia virus, which is not a natural human pathogen, and is designed to selectively kill tumor cells while sparing healthy tissue.This novel therapy not only directly attacks tumor cells but, in doing so, also stimulates the immune system to recognize and destroy tumors and alters the tumor to potentially make it more susceptible to other therapies, offering a three-pronged approach to treatment.

One of the most promising aspects of Olvi-Vec is its potential to overcome ovarian tumor insensitivity to platinum-based chemotherapy. Platinum resensitization aims to remodel the tumor microenvironment of cancer cells to be responsive to platinum-based chemotherapy, which is a long-sought-after goal and has been referred to as the “Holy Grail” of gynecologic oncologists. This is where Genelux’s approach has shown significant promise, offering a new strategy to (re-)sensitize cancer cells to platinum-based therapies.

Recently, a Phase 2 trial using Olvi-Vec, an investigational oncolytic immunotherapy, demonstrated promising data regarding response rate, progression free survival, and clinical reversal of platinum resistance and refractoriness among heavily-pretreated patients (median 4 prior lines) with platinum resistant and refractory ovarian cancer (PRROC).In fact, some platinum-refractory participants in the trial, when re-challenged with a platinum-based regimen after receiving a single cycle of the oncolytic viral immunotherapy, achieved progression free survival exceeding any prior lines.In one case, a participant who had up to 9 failed prior lines showed an overall survival of 23 months while enrolled in this Phase 2 study.

The potential impact of Genelux’s novel virotherapy could extend beyond late-stage ovarian cancer. Olvi-Vec as a resensitizing agent to chemotherapies through its immune modulating functions could potentially open the door to new treatment paradigms in earlier stages of ovarian cancer and other cancers that have developed resistance to standard therapies, which could offer renewed hope to patients with limited treatment options.

Raising awareness about the challenges of late-stage ovarian cancer is crucial for driving change.

: Patient advocacy groups play a key role in highlighting the needs of individuals with late-stage ovarian cancer. Advocacy efforts can help drive increased research funding, better treatment options, and improved patient support services.

: Educating the public about the realities of late-stage ovarian cancer can foster greater empathy and support. Awareness campaigns can also help in reducing the stigma associated with the disease and encourage more individuals to seek early diagnosis and treatment.

: Building strong support networks for patients and their families can provide emotional and practical assistance. Support groups, counseling services, and patient education programs can help individuals navigate the challenges of late-stage ovarian cancer.

Addressing the challenges of late-stage ovarian cancer requires a multi-faceted approach that includes expanding treatment options, increasing research efforts, and raising awareness. As the medical community and society work together to improve the understanding and management of this aggressive disease, there is hope for better outcomes and a brighter future for those affected.

Sponsored by Genelux Corporation

Facing the Challenges of Late-Stage Ovarian Cancer: Navigating Limited Treatment Options and Advocating for New Therapies

Latest News